In this episode of Boston Scientific Talks, Peter Pattison, President, Interventional Oncology, and Liza Davis, VP of R&D, Interventional Oncology, share insights into the acquisition of Obsidio and the integration of its unique gel embolic material technology into Boston Scientific's portfolio.

The technology, described as a "conformable solid," offers a unique balance between a liquid and solid embolic, providing physicians with precise control and rapid occlusion during interventional oncology procedures. The discussion also covers the successful transition from FDA approval to commercialization, with Obsidio technology already being used in several cases. Looking ahead, Pattison and Davis discuss the potential for further applications of the technology and its integration with Boston Scientific's new coil products.

This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.com/medical.

Thank you for listening to the Boston Scientific Talks Podcast.

Subscribe to this podcast on every major podcast platform.

How Boston Scientific's acquisition of Obsidio is shaping its interventional oncology business

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

How Boston Scientific's acquisition of Obsidio is shaping its interventional oncology business

DeviceTalks

Related tracks